New AI tool that provides treatment plan for asthma may lead to sufferers being symptom-free
A new technology that helps treat asthmatics is hoped to be a step towards the “holy grail” of respiratory medicine and available next year.
Conditions
Don't miss out on the headlines from Conditions. Followed categories will be added to My News.
A Victorian-based company is using AI to help “map” and personalise the best treatment for patients with respiratory conditions such as asthma, chronic obstructive pulmonary disorder and chronic sinusitis so they can become free of all symptoms.
The biotech company Diag-Nose.io says the world-first technology should not only help reduce medical costs, but also improve outcomes for the serious respiratory conditions that affect more than one million Australians.
The news will come as a breath of fresh air in particular for Melburnians who live in the asthma capital of the world.
Diag-Nose.io said on Wednesday evening it was recruiting 200 Victorians for a clinical study of its flagship diagnostic tool called RhinoMAP and hopes it can be available for use widely as early as next year.
Using AI, the tool precisely matches patients with the right drug based on their individual biology.
A nasal sample is collected using the company’s patented nasal liquid biopsy device and analysed.
The data collected is uploaded into the RhinoMAP platform to determine disease progression, what drugs it might respond to and 48 hours later to recommend the best drugs for a patient.
The company said traditional diagnostic methods for many chronic respiratory conditions had relied on outdated measurement tools and assessments.
It said the processes were flawed and ended in treatment failure for around one in three patients that globally costs hundreds of millions of dollars a year.
The company’s CEO and founder Eldin Rostom said worldwide respiratory diseases impacted more than 450 million people.
“Our system will bring us one step closer towards the holy grail of respiratory medicine; helping patients become completely free of symptoms,” he said.
Diag-Nose.io, which has its headquarters in Melbourne, has also received a Breakthrough Victoria investment of $800,000 to help it deliver the device and to create more highly skilled jobs.
This Victorian Government program invests in innovation, entrepreneurs and ideas to help accelerate technologies that can make a difference to Victorians while also supporting business grown and jobs.
The Minister for Economic Growth and Jobs Danny Pearson said the investment in Diag-Nose.io would help support the delivery of the device.
“We’re backing Diag-Nose.io so they can get their lifesaving products into market to help people in Australia and around the world who are living with these conditions,” Mr Pearson said.
“It not only creates jobs right here in Victoria, it also drives economic growth and strengthens our reputation as a global leader in medtech.”
Mr Rostom said by using AI the RhinoMAP removed the guesswork and this would enable doctors to match treatments to a patient’s unique biological profile, or “endotype”.
For information on the clinical trials visit Diag-Nose.io
Elderly and sick miss out on this vaccine due to extreme cost
Elderly people are being urged to get this one-off vaccine to protect against a deadly virus. But many can’t even afford it.
The four things you can do now to delay dementia
People who took part in a world-first program that involved making changes in these four key areas experienced major benefits expected to delay dementia’s onset.